Hence, we suggest that genes included in these pathways may be used as markers for CML development (FOS, TGFBR2, TPX2) and CML resistance to therapy (LAPTM4B, HLTF, PIEZO2, CFH, CD109, ANGPT1). The gene discussed is TPX2; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.